Synthesis and neuropharmacological activity of some quinoxalinone derivatives

African Journal of Biotechnology

Volumn 6, Issue 6, 2007, Pages 777-786

  Olayiwola, G ^a   Obafemi, C A ^a   Taiwo, F O ^a  

^a OBAFEMI AWOLOWO UNIVERSITY   (Nigeria)

Author keywords

Anticonvulsant activity; Anxiolytic activity; Quinoxalin 2 ones; Quinoxaline 2,3 diones; Sedative effect

Indexed keywords

1,2,3,4 TETRAHYDROQUINOXALINE 2,3 DIONE; 2,3 DIOXO 1,2,3,4 TETRAHYDROQUINOXALINE 6 SULFONYL AZIDE; 2,3 DIOXO 1,2,3,4 TETRAHYDROQUINOXALINE 6 SULFONYL CHLORIDE; 3 (2 AMINOPHENYL) QUINOXALIN 2(1H) ONE; 6 CHLORO 1,4 DIHYDROQUINOXALINE 2,3 DIONE; 6 METHYL 1,4 DIHYDROQUINOXALINE 2,3 DIONE; 6 NITRO 1,4 DIHYDROQUINOXALINE 2,3 DIONE; AMPA RECEPTOR ANTAGONIST; DIAZEPAM; N [2 (3 OXO 3, 4 DIHYDROQUINOXALIN 2 YL)PHENYL] ACETAMIDE; N,N DIBENZYL 2,3 DIOXO 1,2,3,4 TETRAHYDROQUINOXALINE 6 SULFONAMIDE; QUINOXALINE DERIVATIVE; QUINOXALINONE DERIVATIVE; UNCLASSIFIED DRUG;

ANALGESIA; ANIMAL EXPERIMENT; ANTICONVULSANT ACTIVITY; ANXIETY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG SYNTHESIS; FEMALE; LD 50; LOCOMOTION; MALE; MEMORY; MOUSE; NONHUMAN; RAT; SEDATION; STRUCTURE ACTIVITY RELATION; TRANQUILIZING ACTIVITY;

MUS; RATTUS;

EID: 34047146918     PISSN: None     EISSN: 16845315     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Abdel-Barry JA, Al-Hakein MHH (2000). Acute intra-peritoneal and oral toxicity of the leaf glycosidic extract of Trigonella foenum-graecum in mice. J. Ethnopharmacol. 70: 65-68.
2. Ajayi AA, Ukponmwam OE (1994). Evidence of angiotensin II and endogenous opioid modulation of movelty-induced rearing in the rat. Afr. J. Med. Med. Sci. 23: 287-290.
3. Ali MM, Ismail MMF, El-Gaby MSA, Zahran MA, Ammar YA (2000). Synthesis and antimicrobial activities of some novel quinoxalinone derivatives. Molecules 5: 864-873.
4. Badran MM, Abouzid KAM, Hussein MHM (2003). Synthesis of certain substituted quinoxalines as anti-microbial agents, Part II. Arch. Pharm. Res. 26: 107-113.
5. Brown RE, Corey S, Moore AK (1999). Differences in measures of exploration and fear in MHC-Congenic C57BL/6J and B6-H-2K mice. Behavior Genetics. 26: 263-271.
6. Carta A, Sanna P, Gherardini, Usai D, Zanetti S. (2001). Novel functionalized pyrido[2,3-9]quinoxalinones as antibacterial, antifungal and anticancer agents. Il Farmaco 56: 933-938.
7. Chimirri A, Gitto R, Zappala M (1999). AMPA receptor Antagonists. Expert Opinion on Therapeutic Patents. 9: 557-570.
8. Crowther AF, Curd FHS, Davey DG, Stacey GJ. (1949). Synthetic antimalarials. Part XXXIX. Dialkylaminoalkyl-aminoquinoxalines. J. Chem. Soc. pp. 1260-1262.
9. Dimmock JR, Baker GB (1994). Anticonvulsant activities of 4-bromobenzaldehyde semicarbazone. Epilepsia 35: 648-655.
10. El-Gendy AA, El-Meligie S, El-Ansary A, Ahmedy AM (1995). Synthesis of some quinoxaline derivatives containing indoline-2,3-dione or thiazolidine residue as potential antimicrobial agents. Arch. Pharm. Res. 18: 44-47.
11. El-Hawash SA, Habib NS, Fanaki NH (1999). Quinoxaline derivatives Part II: Synthesis and antimicrobial testing of 1,2,4-triazolo[4,3-a]quinoxalines, 1,2,4-triazino[4,3-a]-quinoxalines and 2-pyrazolylquinoxalines. Pharmazie 54: 808-815.
12. Glantz AS (1992). Primer of Biostatistics (Version 3.02). McGraw-Hill Inc.
13. Haefely W (1984). The biological basis of the psychotropic action of drugs. In: Poldinger W (ed). Compendium of Psychopharmacotherapy. Editiones Roche, Basle, Switzerland, pp. 19-47.
14. Handley SL, Mithani S (1984). Effects of α-adrenoceptor agonists and antagonists in a maze-exploration model of 'fear'-motivated behaviour. Naunyn-Schmiedeberg's Arch. Pharmacol. 327: 1-5.
15. Hayes WA (1989). Principles and Methods of Toxicology 2nd Edition. New York. Raven Press Ltd. pp. 221-226.
16. Jaso A, Zarranz B, Aldana I, Monge A (2003). Synthesis of new 2-acetyl and 2-benzoylquinoxaline 1,4-di-N-oxide derivatives as anti-mycobacterium tuberculosis agents. Eur. J. Med. Chem. 38: 791-800.
17. Kodama M, Yamada N, Sato K, Kitamura Y, Koyama F, Sato T, Morimoto K, Kuroda S (1999). Effects of YM90K, a selective AMPA receptor antagonist, on amygdalakindling and long-term hippocampal potentiation in the rat. Eur. J. Pharmacol. 374: 11-19.
18. Kurasawa Y, Muramatsu M, Yamazaki K, Tajima S, Okamoto Y, Takada A (1986b). A facile synthesis of 1-aryl-3-heteroaryl-1H-pyrazolo[3,4-6] quinoxalines and related compounds with antifungal activity [1]. J. Heterocyclic Chem. 23: 1391-1394.
19. Le Bars D, Gozariu M, Cadden SW (2001). Animal models of nociception. Pharmacological Reviews 53: 598-643.
20. Lister RG (1987). The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology, 111: 323-331.
21. Lister RG (1990). Ethologically-based animal models of anxiety disorders. Pharmacological Theory 46: 321-340.
22. Locke D (1983). A new approach to practical acute toxicology. Arch. Toxicol. 54: 275-287.
23. Loscher W (1998). New visions in the pharmacology of anticonvulsion. Eur. J. Pharmacol. 342: 1-13.
24. Loscher W, Honack D (1994). Effects of the non-NMDA antagonists NBQX and the 2,3-benzodiazepine GYKI 52466 on different seizure types in mice: comparison with diazepam and interactions with flumazenil. Br. J. Pharmacol. 113: 1349-1357.
25. Loscher W, Lehmann H, Behl B, Seeman D, Teschendorf HJ, Hofmann HP, Lubisch W, Hoger T, Lemaire HG, Gross G (1999). A new pyrrolyl-quinoxalinedione series of non-NMDA glutamate receptor antagonists: pharmacological characterization and comparison with NBQX and valproate in the kindling model epilepsy. Eur. J. NeuroSci. 11: 250-262.
26. Monge A, Martinez-Crespo FJ, Cerain AL, Palop JA, Narro S, Senador V, Marin A, Sainz Y, Gonzalez M, Hamilton E, Barker AJ (1995). Hypoxia-selective agents derived from 2-quinoxaline carbonitrile 1,2-di-N-oxides.2. J. Med. Chem. 38: 4488-4494.
27. Nasr MNA (2002). Synthesis and antibacterial activity of fused 1,2,4-triazolo[4,3-a]quinoxaline and oxopyrimido[2′,1′:5,1]-1,2,4- triazolo[4,3-a]-quinoxaline derivatives. Arch. Pharm. Med. Chem. 8: 389-394.
28. Nordholm L, Sheardown SD, Honore T (1997). In: Excitatory amino acids - clinical results with antagonists. Herrling, PL (Ed.). Academic Press, London, pp. 89-97.
29. Obafemi CA, Akinpelu DA (2005). Synthesis and antimicrobial activity of some 2(1H)-quinoxalinone-6-sulfonyl derivatives. Phosphorus, Sulfur, Silicon Relat. Elem. 180: 1795-1807.
30. Obafemi CA, Pfleiderer W (1994). Permanganate oxidation of quinoxaline and its derivatives. Helv. Chim. Acta 77: 1549-1556.
31. Olayiwola G (2005). Neuropharmacological properties of Stachytarpheta cayennensis leaves (L.C. Rich) vahl (Verbenaceae). Ph.D Thesis, Obafemi Awolowo University, Nigeria.
32. Pandeya SN, Yogeeswari P, Stables JP (2000). Synthesis and anticonvulsant activity of 4-bromophenyl substituted aryl semicarbazones. Eur. J. Med. Chem. 35: 879-886.
33. Pellow S, Chopin Ph, File SE, Briley M (1985). Validation of open-closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Meth. 14: 149-167.
34. Randall LO, Selitto JJ (1957). A method for measurement of analgesic activity on inflamed tissue. Arch. Int. Pharmacodyn. 111: 409-419.
35. Rangisetty JB, Gupta CNVHB, Prasad AL, Srinivas P, Sridhar N, Parimoo P, Veeranjaneyulu A (2001). Synthesis of new arylaminoquinoxalines and their antimalarial activity in mice. J. Pharmacy and Pharmacology 53: 1409-1413.
36. Reddy DS, Kulkarni SK (1997). Differential anxiolytic effects of neurosteroids in the mirrored chamber behaviour test in mice. Brain Research. 752: 61-71.
37. Refaat HM, Moneer AA, Khalil OM (2004). Synthesis and antimicrobial activity of certain novel quinoxalines. Arch. Phram. Res. 27: 1093-1098.
38. Ries UJ, Priekpe HW, Havel NH, Handschuh S, Mihm G, Stassen JM, Wienen W, Nar H (2003). Heterocyclic thrombin inhibitors. Part 2: quinoxalinone derivatives as novel, potent antithrombotic agents. Bioorg. Med. Chem. Lett. 13: 2297-2302.
39. Rogawski MA, Donevan SD (1999). AMPA receptors in epilepsy and as targets for antiepileptic drugs. Adv. Neurol. 79: 947-963.
40. Sanna P, Carta A, Loriga M, Zanetti S, Sechi L (1999). Synthesis of 3,6,7-substituted-quinoxalin-2-ones for evaluation of antimicrobial and anticancer activity. Part 2: Il Farmaco 54: 161-168.
41. Sanna P, Carta A, Loriga M, Zanetti S, Sechi L (1999). Preparation and biological evaluation of 6/7-trifluoromethyl(nitro) - 6,7-difluoro-3-alkyl(aryl) -substituted-quinoxalin-2-ones. Part 3: Il Farmaco 54: 169-1177.
42. Sarges R, Howard HR, Browne RG, Lebel LA, Seymour PA, Koe Bk (1990). 4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants. J. Med. Chem. 33: 2240-2254.
43. Siqueira IR, Lara DR, Silva D, Gaieski FS, Nunes DS, Elisabetsky E (1998). Psychopharmacological properties of Ptochopetalum olacoides Bentham (Oleaceae). Pharm. Biol. 36: 327-334.
44. Su D-S, Bock MG (2005). 2-Quinoxalinone derivatives as bradykinin antagonists and novel compounds. US Patent Appl. (20050020591).
45. Trullas R, Skolnick P (1993). Differences in fear motivated behaviour among in-bred mouse strains. Psychopharma-cology 111:323-331.
46. Ukponmwan OE, Rupreht J, Dzolijie M (1986). An analgesic effect of enkephalinase inhibition is modulated by monoamine oxidase-B and REM sleep deprivations. Naunyn-Schmiedeberg's Arch. Pharmacol. 332: 376-379.
47. United States Environmental Protection Agency (USEPA) (2004). Probit analysis program for the determination of LC/EC values, Version 1.5 (Web resource www.usepa.gov).
48. Vogel GH (2002). Pharmacology Core Battery Tests. In: Drugs Discovery and Evaluation, 2nd Edition, Springer Publishers, Berlin, pp. 385-544.
49. Wafai ZA, Mehta VL (1986). Some neuropharmacological actions of 3-methyl-5-phenyl-(4′-methyl)-quinolenodiazepine. Indian J. Pharmacol. 18: 89-94.
50. Warner PL, Luber EJ (1979). 1-(2-Acylamino-phenyl)imidazoles. U.S. Patent, 4,172,647[Chem. Abstr. 1980, 92:58785a]
51. Wendt GR, Ledig KW (1969). 6,7-Dihydroxy-1H-pyrazolo[3,4-6]quinoxaline-5, 8-diones. U.S. Patent, 3,431,262 [Chem. Abstr. 1969. 70: 106512).
52. Wiedermannova I, Slouka J, Hlavac J (2000). Oxoderivatives of quinoxaline II. The study of reactivity of 2-(2-oxo-1,2-dihydroquinoxaline-3-yl)benzenyl cation. Acta Universitatis Palackianae Olomucensis, Facultas Perum Naturalium 39: 69-74.